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Summary. Objectives: To compare the usefulness of HRCT of the chest versus spirometric
measures (PFTs) in evaluating the effect of tobramycin solution for inhalation (TSI) in cystic fibrosis
(CF). Methods: Thirty-two CF patients with mostly mild lung disease age6 years, were enrolled in
a double-blind, placebo-controlled pilot study. Patients were chronically colonized with
Pseudomonas aeruginosa for at least 6 months prior to and at enrollment. If patients were on
TSI, they were taken off for at least 3 months prior to enrollment. Duration was 6 months; 31
subjects completed the study. HRCT and PFTs were evaluated at baseline, after 28 days of
treatment and at the end of the study. Study medication was administered as 5 ml nebulized
treatment twice a day for 28 days followed by 28 days off (one cycle). Study consisted of three
cycles. Two radiologists scored all films using a validated system. A total HRCTscore consists of
the sum of subscores: linear opacities, hyperinflation, nodular opacities, peribronchial thickening,
mucous plugging, and bronchiectasis; each subscore could range from 0 to 80, with potential total
scores varying from 0 to 480. The percent of the maximum possible HRCT score was then
calculated and used for all comparisons. Results: Using two tailed paired t-test, the percent
maximum HRCT score decreased by 1.42.6% (meanSD) (P¼ 0.049) and 0.32.8%
(P¼0.63) for the TSI group and decreased by 0.1 1.5% (P¼0.74) and increased by 0.61.8%
(P¼0.23) for the placebo group between visits 1 and 2, and visits 1 and 3, respectively. The data
were then analyzed using a mixed model utilizing changes in scores over the durations of the study
for each group. The change of HRCTscore for the TSI group was0.24/day (P¼ 0.02) and0.03/
day (P¼ 0.22), and for the control group the change was 0.01 (P¼0.93) and 0.02 (P¼0.29)
between visits 1 and 2, and visits 1 and 3 respectively. FEF25–75% and FEV1% changes were not
statistically significant using both analyses. Conclusion: HRCT seems to be more sensitive in
detecting treatment effect than PFT in CF patients with mild lung disease, especially following the
first treatment period (visit 2). Total HRCT score showed some improvement at the end of the
study, though not statistically significant. This is probably due to obtaining the HRCT an average
of 30 days after completion of the TSI treatment, and selection of study population with mostly
mild lung disease. This could indicate that the most significant improvement in the total HRCTscore
in this patient population occurs after the first treatment period with TSI. Pediatr Pulmonol. 2010;
45:440–449.  2010 Wiley-Liss, Inc.
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INTRODUCTION
Infants with cystic fibrosis (CF) have normal lungs at
birth.1 Early manifestation of lung disease starts shortly
after birth.1 The predominant causes of early lung disease
in CF are persistent infection and inflammation.2 These
lead to chronic lung disease, progressive worsening in
lung function, and increased morbidity and mortality.2
Median age of survival has been steadily increasing over
the last few decades. Currently, the median survival is
37.4 years of age.3 Detection of early CF lung disease is
essential for understanding the disease progression.4
It has been reported that in mild CF lung disease, the use
of HRCT is more sensitive and superior to chest
radiographs (CXR) in evaluating and monitoring lung
structure.5,6 Pulmonary function tests (PFTs) are widely
used to evaluate and monitor progression of lung disease
in CF patients. However, they are insensitive in localizing
early lung disease and are indirect measure of lung
structure.7 Longitudinal studies using HRCT and spiro-
metry in CF patients revealed significant changes in lung
parenchyma, especially in early stages of the lung disease
using HRCT.8–11 However, in these studies, patients had
normal or stable spirometry findings. These findings
support the notion that PFTs may not be an accurate
measure for monitoring the progression of early lung
disease.8–11
Tobramycin solution for inhalation (TSI) has been
studied and shown effective in CF patients with moderate
to severe lung disease with FEV1 between 25% and 75%
predicted and chronically colonized with Pseudomonas
aeruginosa.12 TSI was studied in CF patients with mild
lung disease and chronic P. aeruginosa colonization.13
One study showed significant reduction in respiratory
hospitalizations, antibiotic use, and improvement (not
statistically significant) in percent predicted forced
expiratory flow (FEF25–75%).
13 The purpose of this pilot
study was to evaluate the effect of TSI on CF patients
6 years with mostly mild lung disease and colonization
with P. aeruginosa using HRCTand PFTas end points. We
hypothesized that HRCT might be more effective than
PFT in evaluating the effect of TSI on CF patients with
mild-moderate lung disease. Previously, we reported
results from the early part of the study.14 The HRCT
score used in the initial analysis was derived from
Brody.11 That score consisted of eight component
scores (bronchiectasis, peribronchial thickening, mucus
plugging, atelectasis, nodular opacities, linear opacities,
inhomogeneity, and hyperinflation). A modified score was
calculated by dropping two discordant component scores
(atelectasis and inhomogeneity). In this study we used the
modified HRCT score in the analysis. In this article, we are
reporting the results of the 6-month study assessing the
effects of TSI versus placebo in this patient population.
MATERIALS AND METHODS
Study Design
This is a randomized, double-blind, placebo-controlled
pilot study. The study procedures and measures were
approved by the University of Michigan Institutional
Review Board. Consent was obtained from patients and/or
parents/guardians prior to enrollment in the study.
Study Population
Patients with CF 6 years of age and older with FEV1
40% predicted, attending the University of Michigan CF
Center, were considered eligible for the study. Thirty-two
patients (12 males and 20 females) with a confirmed
diagnosis of CF by sweat chloride test and/or genotype,
and P. aeruginosa colonization in sputum obtained from
deep pharyngeal culture, for at least 6 months of screening
and at enrollment were recruited. Patients with first
colonization with P. aeruginosa were not recruited.
Exclusion criteria included known hypersensitivity to
aminoglycosides or history of Burkholderia cepacia
isolated from respiratory cultures. Patients had to be
clinically stable prior to enrollment with no hospital-
ization or intravenous antibiotic use for pulmonary
exacerbation within 2 months of enrollment. Also, no
oral antibiotic use within 1 month of enrollment and no
TSI use for at least 3 months prior to enrollment. All
subjects were pancreatic insufficient.
Study Procedures
Enrollment duration was 18 months, from February
2002 to August 2003. Patients were evaluated at baseline,
28 days and at the end of the study. Eligible subjects were
randomized to receive either 5 ml of TSI or 5 ml of placebo
twice a day, via inhalation therapy for 28 days followed by
28 days off medication (one cycle). Study consisted of
three cycles (6 month duration). TSI (Novartis, New
Hanover, NJ) is a solution of 300 mg tobramycin and
11.25 mg sodium chloride in sterile water; the placebo was
chosen for its similar taste to TSI and consisted of 1.25 mg
quinine sulfate in normal saline. Adherence to study
treatments was determined by collecting and counting all
used and unused medication vials that patients were asked
ABBREVIATIONS
CF Cystic fibrosis
FEV1 Forced expiratory volume in one second
FEF25–75% Forced expiratory flow during middle half of forced
vital capacity
HRCT High resolution chest tomography
HU Hounsfield unit
PFTs Pulmonary function tests
TSI Tobramycin solution for inhalation
CFQ-R Cystic fibrosis questionnaire.
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to return. Routine CF care was provided for patients as
directed by the primary pulmonologist. Study medication
and placebo were administered using a Pari LC PlusTM jet
nebulizer and a Pulmo-Aide1 compressor. Both TSI and
placebo were supplied by Novartis. The University of
Michigan investigational drug services performed the
randomization and double blinding for the study.
HRCT and spirometry (Sensormedics, Vmax 6200,
Yorba Linda, CA), were obtained at baseline, 28 2 days
and at the end of the study 4 days. Spirometry was
obtained according to ATS guidelines. CXR was done at
baseline for evaluation of lung disease and as part of
routine annual care. Patients were enrolled at the time of
their annual visit. Throat/sputum cultures were obtained
prior to enrollment for confirmation of colonization with
P. aeruginosa. ACF quality of life questionnaire (CFQ-R),
validated for use in CF patients,15 was administered at
baseline and at the end of the study (visit 3) to patients and
parents/guardians. Adverse events, hospitalizations, con-
comitant medication use, and school/work days missed
due to illness, were recorded during the study.
HRCT scan was performed using 40 mA, 1 sec gantry
rotation time, and 120 kVp for each slice through the lung.
Utilizing a HiSpeed Advantage1 scanner (General
Electric Medical Systems, Milwaukee, WI), images were
obtained at 1 mm thickness. Five equally spaced images in
inspiration and in expiration, after an AP inspiratory scout
view, were obtained for a total of 10 images. Patients were
placed in the supine position and instructed to take a deep
breath and hold it for 7–10 sec. During each breath hold,
the five inspiratory sections were obtained. The same
technique was repeated after patients were asked to exhale
to lowest volume and hold their breath for the
expiratory sections. Patients practiced the techniques
prior to the testing and were monitored by both the
radiology technician and the research coordinator. If
techniques were suboptimal, patients were instructed to
repeat them. The superior-most image was at the upper
margin of the posterior 3rd rib and the inferior-most image
was 1 cm above the diaphragm. The range of the effective
radiation dose was estimated to be 0.03–0.05 mSv and the
equivalent radiation dose to the entire lung was estimated
to be 0.09 mGy for each HRCT study. HRCT images were
reviewed on a workstation (Sienet Magicview, version 42,
Siemens, New York, NY). Images were initially displayed
with a window width of 1,000 Hounsfield units (HU) and
level of 600 HU; however, the readers were permitted to
modify the window and level of display of individual
images and examinations for optimal viewing.
Scoring of the HRCT scans and CXRs were performed
by two pediatric radiologists (PJS and BPE). Both readers
were blinded to patient name, number, and study date at
the time of reading and scoring. Each CXR (conventional
analog) was scored twice by each radiologist using the
Brasfield scoring method,16 and the scores were averaged
for the two readers. A CXR score of 25 points indicates a
normal finding, the score decreasing with increasing
severity of lung disease. The HRCT score was derived
from Brody and others.6,17–20 The score was then
modified by dropping two component categories; atelec-
tasis and inhomogeneity as discussed in our previous
work.14 Each reader read each HRCT twice in a
randomized, blinded fashion. Means of the scores for
each reader were calculated separately and compared
between baseline and 28 days and between baseline
and end of study. Scores of both readers were also
combined (four total readings); a mean of the combined
score was calculated and compared between baseline and
28 days and between baseline and end of study. One reader
read the HRCT scans for the second time within 1–
2 weeks from the first reading. The second reader read the
HRCT scans for the second time 1–2 months after the first
reading.
Each lung (right and left) was scored for each of the five
imaging levels. Six imaging component categories were
scored at each level for each lung: nodular opacities, linear
opacities, hyperinflation (lack of normal decrease in
volume on expiratory views), peribronchial thickening
(abnormal thickening of bronchial walls), bronchiectasis
(dilated bronchi usually judged relative to diameter of
adjacent pulmonary artery branch), and mucus plugging
(opacified bronchus/bronchi). Hyperinflation was scored
on expiration since the expiratory images showed this
finding better. The other five component categories were
scored on inspiratory images. Scoring ranged from 0 to 4
with 0 indicating a normal finding and 4 indicating severe
disease. The HRCT final score of each patient was
calculated based on the severity and extent of the
morphologic changes, and represented the score from
the two lungs and was averaged for two readers. Three
summary scores were calculated. (1) A component
category score: the average of both readers’ scores across
the five levels within each category and for both lungs.
(2) An imaging level score: The average of both readers’
scores across six components within each level and for
both lungs. (3) Total score: the sum of all six total HRCT
category scores or the sum of all five level scores. Each
subscore (i.e., component category score) could range
from 0 to 80 [score of 80¼ score of each of the five levels
for each lung (10 scores) which varied from 0 to 4
(maximum of 40) 2 lungs]. The score was the average of
the four readings for the two readers. Potential total scores
varied from 0 to 480.
Statistical Analysis
The primary aim of this study was to evaluate response
to TSI (vs. placebo) using both HRCTand PFTs in order to
obtain preliminary data regarding the relative value of
HRCT as an objective measure of treatment response.
Pediatric Pulmonology
442 Nasr et al.
While the previous publication from this project evaluated
this related to initial treatment response (i.e., immediately
following first TSI treatment),14 this manuscript describes
the results pertaining to longer-term treatment response
(i.e., approximately 30–40 days after completion of third
TSI treatment).
Initial data analysis was performed using descriptive
statistics. Frequencies and percentages were calculated
for categorical variables; mean, median, standard
deviation, minimum, and maximum were calculated for
continuous variables. HRCT data were analyzed as both
absolute score (for individual components and composite)
and as percent of maximum score. HRCT data are
presented herein as percent of maximum score through-
out. As this is a pilot study, power calculations were not
performed. The number of subjects studied was arbitrarily
chosen. The baseline analysis was performed with 16
patients in each treatment group. End of study analyses
included data from 16 patients in the TSI arm and 15
patients in the placebo arm (excluding the drop-out subject
in the placebo arm). SAS version 8 software was utilized
for all analyses. Between-group comparisons were
performed using both the Student’s t-test and the non-
parametric Wilcoxon rank-sum test for continuous data
and using the Chi-squared test for categorical data.
Within-individual comparisons of continuous data (e.g.,
visits 2 and 3 vs. visit 1 within each treatment group) were
performed using the paired t-test. Pearson’s correlation
coefficient was used to describe the relationship between
continuous quality-of-life data and other continuous data.
All applicable statistical tests used were two-sided, and P-
values 0.05 were considered statistically significant.
Coefficient of variation and test of differences in mean
scores between and within readers (mean SD) were used
to measure inter/intra-reader variability in scoring CXR
and HRCT images. Inter/intra-reader reliability analyses
were carried out to test whether there was a difference
between the reliability of the scoring for HRCT and CXR.
The subjects in both groups were combined to enlarge the
sample size for statistical analyses. HRCT scores from
three visits and CXR scores from the first visit were
averaged for these analyses. Analysis was also done for
the total HRCT score, all HRCT subscores, and the CXR
scores.
The HRCT total score, FEF25–75% predicted and
FEV1% predicted changes during the study were analyzed
using a mixed model analysis. The analysis was done
where time was in the unit of days with time¼ 0 for
baseline, time¼ 28–31 for visit 2, and time¼ 168–176
for visit 3. Treatment¼ 0 represented placebo and
Treatment¼ 1 represented TSI. The analysis evaluated
the change in mean total HRCT score, FEF25–75%, and
FEV1% predicted for both groups with 1 day increase
in time for the duration of the study. This analysis was
done to evaluate the cumulative effect of using TSI versus
placebo in this patient population over the duration of the
study.
A frequency distribution of HRCT score differences
was also conducted for the individual scores, by patient
and by case over the three visits to demonstrate
the pattern of scoring for each of the two readers.
Ninety-seven percent of the observations had a
maximum score difference of 1 or less. Maximum
difference¼ (maximum of the four scores, E1, E2, S1,
S2) (minimum of the four scores E1, E2, S1, S2).
RESULTS
Thirty-two patients were enrolled and randomized to
one of the two treatment groups. Thirty-one patients
completed the study. One patient in the placebo group
dropped out of the study after few days of enrolling due to
bad taste of the ‘‘medication.’’ The median overall
treatment adherence rate was 97.6%, with only three
subjects having adherence rates of less than 87.5% (one in
TSI group with a 43.5% adherence rate, and two in placebo
group with 59.5% and 21.4% adherence rates).
Baseline clinical characteristics of the two groups are
presented in Table 1. Most of the study population had
mild to moderate lung disease as indicated by the mean
CXR Brasfield score, mean percent predicted FEV1, and
FEF25–75%, 21.55, 89.7%, and 75.9%, respectively. CXR
was done only at baseline to evaluate disease severity and
as part of routine CF care. Patients randomized to TSI
were younger and had milder lung disease than those
randomized to Placebo. However, there were no signifi-
cant differences between the two groups except for
weight.
The intra-observer difference in the mean HRCT score
for the first reader was P¼ 0.76 and for the second reader
the P-value was 0.48. Non-parametric tests (Wilcoxon
rank-sum) values were 0.51 and 1.00, respectively, which
were consistent with the t-test results. When both readers’
scores were combined, t-test and Wilcoxon rank-sum P-
values were 0.80 and 0.64, respectively. The interval
between the two readings for the first reader was 1–
2 weeks while the interval for the second reader was 1–
2 months.
Mean (SD) time between end of first TSI treatment
and evaluation was 1.4 (2.0) days in the TSI group and
1.4 (1.5) days in the placebo group. Mean time between
the end of the third TSI treatment and evaluation was 30.2
(8.0) days in the TSI group and 29.5 (8.2) days in the
placebo group. The total HRCT and six component scores
for each visit and the difference between visits 1 and 2 and
visits 1 and 3 are illustrated in Tables 2A and 2B. Using
two tailed paired t-test, the percent maximum HRCT score
decreased by 1.4 2.6% (mean SD) (P¼ 0.049) and
0.3 2.8% (P¼ 0.63) for the TSI group and decreased by
0.1 1.5%, (P¼ 0.74) and increased by 0.6 1.8%,
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(P¼ 0.23) for the placebo group between visits 1 and 2,
and visits 1 and 3, respectively. Figure 1A and B represents
Total HRCT score for individual patients in TSI and
placebo groups, respectively. Most subjects had mild lung
disease as indicated by the low total HRCT score. Patients
with more severe disease showed significant improvement
in total HRCT score (n¼ 1) and no change in total HRCT
score in the placebo group (n¼ 2).
The mean difference between visits 2 and 1 and visits 3
and 1 for FEF25–75% for the TSI groups were 4.54 21.60
(SD) (P¼ 0.23) and 1.79 26.27 (P¼ 0.64) and for
placebo group were 0.40 8.33 (P¼ 0.41) and
3.87 22.88 (P¼ 0.58). The mean difference between
visits 2 and 1 and visits 3 and 1 for FEV1 for the TSI
group were 0.60 14.15 (P¼ 0.70) and 4.13 17.75
(P¼ 0.43) and for placebo group were 1.33 6.18
(P¼ 0.48) and 2.20 8.50 (P¼ 0.24). Figure 2 illustrates
some of the inspiratory images of one patient that was
randomized to TSI. Patient had moderate lung disease
with FEV1 of 70% of predicted.
The mixed model analysis results are summarized in
Table 3. The P-value for the TSI group between visits 1
and 2 was statistically significant (P¼ 0.02) in this model.
There was some improvement (not statistically signifi-
cant) in the HRCT score for the TSI group between visits 1
and 3 (P¼ 0.22) and in the FEF25–75% for the TSI group
between visits 1 and 2 (P¼ 0.12).
There was no statistical difference between the two
readings of HRCT for each of the two readers (intra-
observer difference) using either parametric (Student’s
t-test) or non-parametric (Wilcoxon rank-sum) statisti-
cal tests. In addition, there was no statistical
difference between the two readers values (inter-observer
variability).
Table 4 summarizes the antibiotics use during the study
period. The antibiotics use was a marker for pulmonary
exacerbation during the study period. There was statistical
significance between the TSI and placebo groups for the
total antibiotic courses, oral antibiotics courses, and days
on oral antibiotics with P¼ 0.012, <0.01, and <0.01,
respectively. CFQ-R data were analyzed. There was a poor
correlation (r¼ 0.28) between CFQ-R and HRCT score.
In addition, there was no statistical significance between
baseline and end of study for both groups.
DISCUSSION
In this pilot study, there was significant improvement in
HRCT score after 28 days of TSI versus no improvement
in placebo group. At the end of the study (approximately
28–36 days after completion of study medication),
however, there was no significant change in HRCT score.
This lack of improvement could be due to the several-
week delay between completion of the study medication
and the final study examination. Alternatively, this could
indicate that the most significant improvement in HRCT
score in this mostly mild patient population occurred after
the first cycle of TSI. It has been reported that TSI is most
effective in patient with moderate to severe (FEV1 25–
75% predicted) lung disease.12 This is the first study, to
the best of our knowledge, that used HRCT to evaluate the
short-term (28 days) and long-term effects (after three
cycles) of TSI in mild CF patients.
The limitation of only five cuts for inspiratory and five
expiratory HRCT scans may have been another cause of
limiting the ability to discern significant difference after
the three cycles of TSI treatment in this mild patient
population. The use of limited cuts reduces the sensitivity
to detect changes as documented recently.9,21–23 How-
ever, using limited cuts reduces radiation dosing that
patients are exposed to. In this protocol, there were
specific instructions on how and where to place the five
Pediatric Pulmonology
TABLE 1— Baseline Characteristics of Study Population
TSI Placebo P-value1
Number of patients 16 16
Gender (M/F) 6/10 6/10
Age (years) 11.81 7.462 (6.0–34.7)3 15.86 7.25 (7.4–28.8) 0.13
Weight (kg) 34.83 14.08 (17.6–62.0) 46.38 16.92 (21.9–73.3) 0.04
Weight for age (percentile) 25% 10%
FEV1% predicted 95.73 17.21 (55.0–134.1) 83.71 21.07 (40.00–108.73) 0.09
FEF25%–75% predicted 81.71 22.94 (29.35–111.83) 70.04 31.19 (11.40–110.14) 0.24
Total HRCT score 23.47 14.60 (6.75–60.5) 25.10 17.81 (5.00–73.25) 0.78
Total HRCT score % of maximum score 4.89 3.04% (1.41–12.60%) 5.23 3.71% (1.04–15.06) 0.78
CXR Brasfield score 22.05 1.32 (18.8–24) 21.05 2.88 (14.8–25) 0.22
Sweat chloride (meg/L) 101.1 17.75 (70.0–134.0) 106.8 18.03 (80.0–145.0) 0.58
Genetic analysis
Homozygous delta F508 8 11
Heterozygous delta F508 2 2
1Student’s t-test for two independent samples (two tailed).
2Mean SD.
3Range.
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slices at each study. This should result on each slice being
in the same vicinity of the previous one, but not the exact
position. The choice of the limited number of cuts to five
scans during inspiration and five during expiration was
determined following our previous work.5 The number of
cuts in this study was thought to be reasonably
representative of the disease present and changes that
occurred. The effective and equivalent doses of radiation
from HRCT in this study was approximately equal to two
CXRs (PA and lateral view each), even though the
radiation dose is delivered in a different manner for both
procedures (effective dose was 0.04 and 0.02 mSv and the
equivalent doses were 0.09 and 0.04 mGy, respectively).
Axial HRCT images in inspiration at two levels from a
patient in the TSI group at baseline, 28 days and at end of
study are shown in Figure 2. The changes in HRCT score
by each reader and by both reader were analyzed. The
intra-observer variability was higher with the longer
interval (1–2 months) between the two readings versus
lower variability with the shorter interval (1–2 weeks).
This is consistent with prior observation.24
Changes in HRCT component scores for individual
patients are shown in Figure 1A and B. Changes of the
total HRCT score and component scores are summarized
in Tables 2A and 2B. In this study, it was noted that
peribronchial thickening, hyperinflation, and linear opac-
ities were the most useful component scores, overall.
Nodular opacities and bronchiectasis seemed only mar-
ginally useful, and mucus plugging was of little value. For
comparing treated versus non-treated patients (i.e., TSI vs.
placebo), peribronchial thickening seemed best (only
component to show significant differences, both early
(V2) and later (V3) after treatment), with hyperinflation
(measure showing biggest absolute difference) and linear
opacities (relatively large differences and one of least
Pediatric Pulmonology
Fig. 1. A: Total HRCT score for individual subjects in the TSI
group. B: Total HRCT score for individual subjects in the placebo
group. Solid symbols, TSI group; open symbols, placebo; solid
bars, mean values for each visit.
Fig. 2. A–F: Inspiratory HRCT images obtained at baseline
(A,B), at 28 days (C,D), and at the end of study (E,F). Images A, C,
and E correspond as the middle of five images (Level 3). Images
B, D, and F correspond as the lowest of five images (Level 5). The
initial images (A,B) show nodular opacities (white arrow),
bronchiectasis (arrowhead), mild bronchial wall thickening and
mucous plugging (black arrow). Findings are dramatically
improved at 28 days (C,D) and demonstrate slight additional
improvement at the end of study (E,F).
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variable measures) also of some value. For evaluating
treatment response within an individual patient, linear
opacities seemed best (only significant difference in
paired analysis of TSI group), with hyperinflation (biggest
absolute difference) and peribronchial thickening (large
difference and relatively low variability) also useful. Of
interest, the baseline bronchiectasis score was third
highest (following peribronchial thickening and hyper-
inflation) at 9.9 6.2% and 13.4 10.3% for TSI and
placebo group, respectively. That indicates that in this
mostly mild patient population, the changes in the lungs as
indicated by HRCT are more severs than expected.
There was significant improvement in HRCT score after
28 days of TSI treatment, while there was no significant
improvement using FEF25–75% or FEV1% predicted.
Using HRCT as an objective measure to evaluate
treatment effect in CF patients with mild lung disease
could be a reasonable alternative to pulmonary function
testing, first in the research setting and eventually in the
clinical setting once the scoring system and technique are
standardized. These results were not surprising since
pulmonary function testing provides a global measure of
lung function, whereas, on the other hand, areas with
localized abnormalities can be feasibly demonstrated on
HRCT scans.25
It has been reported that HRCT is a more sensitive
measure in detecting early lung disease in CF.8–11 It is also
reported that in pediatric bronchiectasis of different
etiologies, substantial structural damage was evident on
HRCT scores in the absence of abnormalities in
pulmonary function testing.26–28 HRCT has been used
as an end point for therapeutic trials. In a previous study
we evaluated the efficacy of rhDNase in CF patients
younger than 5 years of age using HRCT and CXR as end
points.5 We concluded that administration of rhDNase was
associated with improvement in the HRCT in this young
CF population compared to placebo group while CXR
score was not significantly different between the two
groups.5 In another study, rhDNase intervention versus
placebo in patients with mild CF lung disease was done.29
A spirometer-triggered HRCT and spirometry were used
as end points. The conclusion from this study was that
quantitative air trapping is a more consistent sensitive
outcome measure than either spirometry or total HRCT
scores. It was able to discriminate differences in treatment
effects in children with minimal CF lung disease.29
HRCT has been used as an outcome surrogate in few
studies to evaluate acute pulmonary exacerbation and
response to treatment.17,19,20 Mucus plugging, centrilob-
ular nodules, peribronchial thickening, and overall
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TABLE 4— Antibiotics Use During the Study Period
TSI Placebo P-value
Number 16 15 —
Total antibiotic courses 22 (1.38 1.86) 42 (2.8 1.42) 0.012
Oral antibiotic courses 21 (1.31 1.78) 41 (2.73 1.39) <0.01
Days on oral antibiotics 277 (17.3 25.4) 721 (48.1 45.8) <0.01
Intravenous antibiotic courses 1 1 NS
Number of hospitalizations 1 1 NS
Days on intravenous antibiotics 21 24 NS
NS¼ not significant (>0.05).
TABLE 3— Mixed Model: Mean Changes in HRCT Score, FEF25–75% and FEV1% Predicted
With 1 Day Increase in Time
TSI Placebo
Mean change P-value Mean change P-value
HRCT score
V1–V2 0.24 0.02 0.01 0.93
V1–V3 0.03 0.22 0.02 0.29
FEF25–75% predicted
V1–V2 0.29 0.12 0.05 0.69
V1–V3 0.02 0.72 0.01 0.76
FEV1% predicted
V1–V2 0.08 0.50 0.01 0.96
V1–V3 0.01 0.61 0.00 0.83
V, visit.
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appearance were potentially reversible findings in symp-
tomatic patients in all three studies.17,19,20 HRCT
accurately revealed disease severity and correlated with
clinical improvement as determined by PFT.20
Oral antibiotic courses and days on antibiotics were
both significantly less in the TSI versus placebo group
(P< 0.01) (Table 4). There was one course of intravenous
antibiotics and one hospitalization in each group. The
significant difference in the oral antibiotic use and days on
oral antibiotics with no difference on intravenous anti-
biotics could be due to the mostly mild patient population.
Pulmonary exacerbations in the study subjects were mild
in nature and were successfully treated with oral anti-
biotics. That is in contrast to the moderate–severe patient
population which showed significant difference between
the two groups, in the use of intravenous antibiotics and
hospitalization rate which indicated more severe pulmo-
nary exacerbations.12 This finding could be justification
for future study to evaluate the usefulness of different
antibiotic treatment modalities in this mild CF patient
population.
Analysis of objective (HRCT score) and subjective
(CFQ-R) outcomes was done between baseline and end of
study. Analysis was stratified by baseline HRCT score.
There was an overall poor correlation (r¼ 0.28) between
CFQ-R and HRCT score. Removal of outliers from the
analysis only modestly improved the correlation (increase
r from 0.28 to 0.34). Best correlation between change in
HRCT and change in CFQ-R was for those in the middle
percentile of baseline HRCT score (i.e., 20.25–32.35)
with correlation of r¼ 0.58–0.8. An evaluation of parents/
care givers-assessed CFQ-R for patients 6–13 years of age
versus patients-assessed CFQ-R was done. There was a
general agreement between the two groups (r¼ 0.62).
This close relationship is identical in TSI and placebo
groups. Explanations of lack of improvement in CFQ-R
could be due to the small number of patients in this pilot
study. In addition, it could have been influenced by
the time spent performing the treatment and the
unpleasant taste of medication. One could conclude that
using subjective measures like CFQ-R to detect TSI
treatment effect has to be used with caution. The objective
measures (HRCT score, FEF25–75% and FEV1) all
correlated well with one another, but poorly with the
subjective measures (CFQ-R).
Limitations of the study include:
1. This is a pilot study with small sample size in
subject groups. A larger study would be of interest
to further evaluate the usefulness of HRCT in this
patient population. Another complicating factor in
the interpretation of these findings is that patients
randomized to TSI were generally younger and had
milder lung disease (though not to a statistically
significant degree).
2. The use of different time intervals between the end of a
treatment and examination (i.e., approximately 1.4 days
for V2 vs. 30 days for V3) complicates any attempted
direct comparison of first-cycle versus third-cycle
response.
3. Findings on expiratory images (hyperinflation) were
dependent on the patient following breath holding
instructions closely. A suboptimal expiratory effort
could mimic hyperinflation. The importance of mon-
itoring volume has been reported.19,29 Lack of adequate
volume monitoring may have increased the variability
of this potentially useful component.
4. The use of limited HRCT cuts could have been a
reason that led to reduction of the sensitivity to
detect changes at the end of the study. In addition,
that could have limited the matching of airways and
regional parenchyma on serial HRCT scans during
the study duration.
CONCLUSION
. HRCT can be a sensitive measure of change in mild CF
pulmonary disease.
. HRCT is likely to require a smaller sample size than
FEV1 or FEF25–75% to demonstrate a significant treat-
ment effect in patients with mild lung disease especially
after first 28 days on TSI.
. The limited number of slices with low mA and/or
scan time reduces the radiation dose.
. CFQ-R may not be a useful measure in detecting a TSI
treatment difference in this mostly mild patient
population.
. The use of antibiotics, especially oral and number
of days on antibiotics is a useful end point in evaluating
treatment effect in this patient population.
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Hendricks JJE, Paré PD, Tiddens HAWM. Pulmonary disease
assessment in cystic fibrosis; comparison of ct scoring systems
and value of bronchial and arterial dimension measurements.
Radiology 2004;231:434–439.
25. Long FR, Williams RS, Castile RG. Structural airway abnormal-
ities in infants and young children with cystic fibrosis. J Pediatr
2004;144:154–161.
26. Santamaria F, Montella S, Camera L, Palumbo C, Greco L, Boner
AL. Lung structure abnormalities, but normal lung function in
pediatric bronchiectasis. Chest 2006;130:480–486.
27. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non-
CF bronchiectasis: clinical and HRCT evaluation. Pediatr
Pulmonol 2003;35:477–483.
28. Pifferi M, Caramella D, Bulleri A, Baldi S, Peroni D, Pietrobelli
A, Boner AL. Pediatric bronchiectasis: correlation of HRCT,
ventilation and perfusion scintigraphy, and pulmonary function
testing. Pediatr Pulmonol 2004;38:298–303.
29. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F,
Moss RB. Dornase alfa reduces air trapping in children with mild
cystic fibrosis lung disease. Chest 2005;185:2327–2335.
Pediatric Pulmonology
HRCT Use in Evaluating CF Lung Disease 449
